NeuroSense shares surge 10.90% intraday after FDA clears pivotal Phase 3 ALS trial for PrimeC.

NeuroSense surged 10.9% intraday after receiving FDA clearance to initiate its pivotal Phase 3 trial, PARAGON, for PrimeC in treating ALS. The global trial, designed to enroll 300 patients with a 2:1 PrimeC-to-placebo ratio, marks a critical step toward potential commercialization. The adaptive design and high statistical power (>95%) underscore the study's robustness, aligning with the stock's sharp rise as investors anticipate progress in addressing a significant unmet medical need.